Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CRISPR/Cas9 mediated deletion of the adenosine A2AR enhances CAR T cell efficacy [human_CRISPR_A2AKO_RNA-seq]

ABSTRACT: Investigation of the transcriptional profile of stimulated HUMAN CRISPR/Cas9 MOCK and A2ARKO α-lewisY CAR T cells in the presence/absence of NECA

ORGANISM(S): Homo sapiens

PROVIDER: GSE156190 | GEO | 2021/03/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

CRISPR/Cas9 mediated deletion of the adenosine A2AR enhances CAR T cell efficacy [murine_CRISPR_A2AKO_RNA-seq]

Project description:Investigation of the transcriptional profile of stimulated murine CRISPR/Cas9 MOCK and A2ARKO α-HER2 CAR T cells in the presence/absence of NECA

2021-03-29 | GSE156191 | GEO

CRISPR/Cas9 mediated deletion of the adenosine A2AR enhances CAR T cell efficacy [NECA_RNA-seq]

Project description:Investigation of the transcriptional profile of stimulated murine α-HER2 CAR T cells in the presence/absence of NECA and/or SCH58261

2021-03-29 | GSE156189 | GEO

CRISPR/Cas9 mediated deletion of the adenosine A2AR enhances CAR T cell efficacy

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-03-29 | GSE156192 | GEO

CRISPR/Cas9 mediated deletion of the adenosine A2AR enhances CAR T cell efficacy

Project description:CRISPR/Cas9 mediated deletion of the adenosine A2AR enhances CAR T cell efficacy

| PRJNA657017 | ENA

Investigation of the transcriptional profile of stimulated HUMAN CRISPR/Cas9 MOCK and A2ARKO α-lewisY CAR T cells in the presence/absence of NECA

Project description:Investigation of the transcriptional profile of sorted and stimulated CD8 and CD4 murine CRISPR/Cas9 MOCK and A2ARKO α-her2 CAR T cells in the presence/absence of NECA

2021-03-29 | GSE166807 | GEO

CRISPR/Cas9 mediated deletion of the adenosine A2AR enhances CAR T cell efficacy [NECA_RNA-seq]

Project description:CRISPR/Cas9 mediated deletion of the adenosine A2AR enhances CAR T cell efficacy [NECA_RNA-seq]

| PRJNA657022 | ENA

CRISPR/Cas9 mediated deletion of the adenosine A2AR enhances CAR T cell efficacy [murine_CRISPR_A2AKO_RNA-seq]

Project description:CRISPR/Cas9 mediated deletion of the adenosine A2AR enhances CAR T cell efficacy [murine_CRISPR_A2AKO_RNA-seq]

| PRJNA657024 | ENA

CRISPR/Cas9 mediated deletion of the adenosine A2AR enhances CAR T cell efficacy [human_CRISPR_A2AKO_RNA-seq]

Project description:CRISPR/Cas9 mediated deletion of the adenosine A2AR enhances CAR T cell efficacy [human_CRISPR_A2AKO_RNA-seq]

| PRJNA657021 | ENA

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.

Project description:Adenosine is an immunosuppressive factor that limits anti-tumor immunity through the suppression of multiple immune subsets including T cells via activation of the adenosine A2A receptor (A2AR). Using both murine and human chimeric antigen receptor (CAR) T cells, here we show that targeting A2AR with a clinically relevant CRISPR/Cas9 strategy significantly enhances their in vivo efficacy, leading to improved survival of mice. Effects evoked by CRISPR/Cas9 mediated gene deletion of A2AR are superior to shRNA mediated knockdown or pharmacological blockade of A2AR. Mechanistically, human A2AR-edited CAR T cells are significantly resistant to adenosine-mediated transcriptional changes, resulting in enhanced production of cytokines including IFNγ and TNF, and increased expression of JAK-STAT signaling pathway associated genes. A2AR deficient CAR T cells are well tolerated and do not induce overt pathologies in mice, supporting the use of CRISPR/Cas9 to target A2AR for the improvement of CAR T cell function in the clinic.

| S-EPMC8163771 | biostudies-literature

Antagonism of IAPs enhances CAR T cell efficacy

Project description:Chimeric antigen receptor (CAR) T cell therapy has proven highly successful in the treatment of hematological malignancies, notably acute lymphoblastic leukemia and B cell lymphoma. However, the efficacy of CAR T cells against solid tumors is poor, likely due to tumor-associated immunosuppression. Here, we demonstrate that antagonizing Inhibitor of Apoptosis Proteins (IAPs) with the clinical smac-mimetic, birinapant, significantly enhanced the anti-tumor activity of CAR T cells in a TNF-dependent manner. Enhanced tumor cell death occurred independently of the perforin-mediated granule exocytosis pathway, underscoring the cytotoxic potential of CAR T cell-derived TNF. Importantly, combining CAR T cell therapy with birinapant dramatically reduced established tumor growth in vivo, where either therapy alone was relatively ineffective. Using patient biopsy-derived tumoroids, we demonstrate the synergistic potential of combining CAR T cell therapy with smac-mimetics. Taken together, we identify CAR T cell-derived TNF as a potent anti-tumor effector, which can be further harnessed by smac-mimetics.

2019-02-01 | GSE124140 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data